Respiratory nurse lead Carol Stonham outlines what nurses in primary care need to know about changes in the diagnosis and ...

Inhaled corticosteroids and long-acting bronchodilators help suppress inflammation, while short-acting beta agonists, such as ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

Tiotropium, the first-choice long-acting bronchodilator in COPD, has been studied in severe asthmatics and in COPD patients with a history of asthma, showing an additional bronchodilator effect on ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

These data strengthen our belief that ensifentrine’s novel bronchodilator and non-steroidal ... a dose-ranging trial with glycopyrrolate, a long-acting muscarinic antagonist (“LAMA ...

While asthma often has genetic roots, Dhaka's harsh environmental conditions have led to an increase in people developing ...

GSK's new long-acting drug candidate for severe asthma ... dose inhaled corticosteroids (ICS), plus at least one additional bronchodilator therapy. "As a physician, it is encouraging to see ...

Primary care practices were randomised to use an electronic health record based CDSS, which recommended a specific guideline ...